Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0000855

Citalopram for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Citalopram hydrobromide, 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile hydrobromide

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C20H21FN2O · HBr
Número CAS:
59729-32-7
Peso molecular:
405.30
Número MDL:
MFCD02101306
Código UNSPSC:
41116107
ID de substância PubChem:
329831193
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

citalopram

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

Br[H].CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3

InChI

1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H

chave InChI

WIHMBLDNRMIGDW-UHFFFAOYSA-N

Informações sobre genes

human ... SLC6A4(6532)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Citalopram for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Potent and selective serotonin uptake inhibitor (Ki = 5.4 nM); antidepressant

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1134233

Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard

1134244

Citalopram Related Compound A, United States Pharmacopeia (USP) Reference Standard

1134222

Citalopram Related Compound H, United States Pharmacopeia (USP) Reference Standard

1134197

Citalopram Related Compound G, United States Pharmacopeia (USP) Reference Standard

1134288

Citalopram Related Compound E, United States Pharmacopeia (USP) Reference Standard

1134266

Citalopram Related Compound C, United States Pharmacopeia (USP) Reference Standard

1134255

Citalopram Related Compound B, United States Pharmacopeia (USP) Reference Standard

1134277

Citalopram Related Compound D, United States Pharmacopeia (USP) Reference Standard

1134299

Citalopram Related Compound F, United States Pharmacopeia (USP) Reference Standard

Y0001008

Citalopram hydrobromide, European Pharmacopoeia (EP) Reference Standard

Y0001007

Citalopram hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR1640

Citalopram Hydrobromide, Pharmaceutical Secondary Standard; Certified Reference Material

1134142

R-Citalopram oxalate, United States Pharmacopeia (USP) Reference Standard

PHR1906

Citalopram Related Compound H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1863

Citalopram Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1902

Citalopram Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1904

Citalopram Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1903

Citalopram Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

BP1153

Citalopram hydrobromide, British Pharmacopoeia (BP) Reference Standard

PHR1905

Citalopram Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1901

Citalopram Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1154

Citalopram impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Warning

Frases de perigo

H302,H336,H361d,H412

Classificações de perigo

Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - STOT SE 3

Órgãos-alvo

Central nervous system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Yevheniia Mikheenko et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(6), 1395-1404 (2015-01-15)
Trait anxiety is a risk factor for the development and maintenance of affective disorders, and insights into the underlying brain mechanisms are vital for improving treatment and prevention strategies. Translational studies in non-human primates, where targeted neurochemical and genetic manipulations
Gordon F Buchanan et al.
The Journal of physiology, 592(19), 4395-4410 (2014-08-12)
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in patients with refractory epilepsy. Defects in central control of breathing are important contributors to the pathophysiology of SUDEP, and serotonin (5-HT) system dysfunction may be involved. Here
M D Opal et al.
Molecular psychiatry, 19(10), 1106-1114 (2013-10-30)
Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days)
Jesper T Andreasen et al.
Brain research, 1601, 117-126 (2015-01-13)
Depression and anxiety often co-occur, and conventional monoamine-facilitating antidepressants show efficacy against symptoms in both disorders. Rodent studies indicate that antidepressant effects of monoamine-based antidepressants involve increased α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid glutamate receptor (AMPAR) neurotransmission, and positive allosteric modulators (PAMs) at
Laura Jiménez-Sánchez et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(11), 2673-2680 (2014-05-30)
Paradoxically, N-methyl-D-aspartate (NMDA) receptor antagonists are used to model certain aspects of schizophrenia as well as to treat refractory depression. However, the role of different subunits of the NMDA receptor in both conditions is poorly understood. Here we used biochemical
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica